https://orcid.org/0000-0001-5071-9257
References
- PhRMA. Value-based contracts: 2009-Q1. 2018. USA 2018; [cited 2019 Dec 1]. Available from: http://phrma-docs.phrma.org/files/dmfile/PhRMA_ValueBasedContracts_V9.pdf.
- Nazareth T, Ko JJ, Sasane R, et al. Outcomes-based contracting experience: research findings from U.S. and European stakeholders. J Manag Care Spec Pharm. 2017;23(10):1018–1026.
- Tonks A. Merck offers money back guarantee on finasteride. BMJ. 1994;309(6964):1252–1253.
- Piatkiewicz TJ, Traulsen JM, Holm-Larsen T. Risk-sharing agreements in the EU: a systematic review of major trends. Pharmacoecon Open. 2018;2(2):109–123.
- Kaltenboeck A, Bach P. Value-based pricing for drugs: theme and variations. JAMA. 2018;319(21):2165–2166.
- Garrison LP, Jr, Towse A, Briggs A, et al. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health. 2013;16(5):703–719.
- Espin J, Rovira J, Garcia L. Experiences and impact of European risk-sharing schemes focusing on oncology medicines; [cited 2020 July 1]. Available from: https://pdfs.semanticscholar.org/d137/b85fc61a66b981a99249db9507f49eef30d1.pdf.
- APMNews.com. Celgene a conclu un accord “efficace ou remboursé” avecle CEPS pour Imnovid [article in French]. 2015; [cited 2020 July 1]. Available from: https://www.apmnews.com/Celgene-a-conclu-un-accord-efficace-ou-rembourse-avec-le-CEPS-pour-Imnovid-FS%20256638.html.
- Frisk P, Aggefors K, Cars T, et al. Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden. Eur J Clin Pharmacol. 2018;74(7):971–978.
- Eriksson I, Wettermark B, Persson M, et al. The early awareness and alert system in Sweden: history and current status. Front Pharmacol. 2017;8:674.
- Clopes A, Gasol M, Cajal R, et al. Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFR-mutation positive non-small-cell lung cancer. J Med Econ. 2017;20(1):1–7.
- Garattini L, Curto A. Performance-based agreements in Italy: ‘trendy outcomes’ or mere illusions? Pharmacoeconomics. 2016;34(10):967–969.
- World Health Organization. WHO guideline on country pharmaceutical pricing policies; [cited 2020 July 1]. Available from: https://apps.who.int/iris/bitstream/handle/10665/153920/9789241549035_eng.pdf;sequence=1.
- Uyl-de Groot CA, Löwenberg B. Sustainability and affordability of cancer drugs: a novel pricing model. Nat Rev Clin Oncol. 2018;15(7):405–406.
- Gray C, Kenney JT. Outcomes-based contracting for disease-modifying therapies in multiple sclerosis: necessary conditions for paradigm adoption. Am Health Drug Benefits. 2019;12(8):390–398.
- Luzzatto L, Hyry HI, Schieppati A, et al. Outrageous prices of orphan drugs: a call for collaboration. Lancet. 2018;392(10149):791–794.
- Godman B, Bucsics A, Vella Bonanno P, et al. Barriers for access to new medicines: searching for the balance between rising costs and limited budgets. Front Public Health. 2018;6:328.
- Adamski J, Godman B, Ofierska-Sujkowska G, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res. 2010;10:153.
- Alkhatib NS, Ramos K, Erstad B, et al. Pricing methods in outcome-based contracting-δ1: cost-effectiveness analysis and cost utility analysis-based pricing. J Med Econ. 2020;23(11):1215–1222.
- Alkhatib NS, Ramos K, Erstad B, et al. Pricing methods in outcome-based contracting-δ2: willingness-to-pay-based pricing. J Med Econ. 2020;23(11):1223–1229.
- Alkhatib NS, Erstad B, Ramos K, et al. Pricing methods in outcome-based contracting-δ3: reference-based pricing. J Med Econ. 2020;23(11):1230–1236.
- Alkhatib NS, Bhattacharjee S, McBride A, et al. Pricing methods in outcome-based contracting-δ4: safety-based pricing. J Med Econ. 2020;23(11):1237–1245.
- Alkhatib NS, McBride A, Bhattacharjee S, et al. Pricing methods in outcome-based contracting-δ5: risk of efficacy failure-based pricing. J Med Econ. 2020;23(11):1246–1255.
- Alkhatib NS, Slack M, Bhattacharjee S, et al. Pricing methods in outcome-based contracting-δ6: adherence-based pricing. J Med Econ. 2020;23(11):1256–1265.
- Alkhatib NS, McBride A, Slack M, et al. Pricing methods in outcome-based contracting: integration analysis of the six dimensions. J Med Econ. 2020;23(11):1266–1272.
- Griffith D. Four types of price variation. Presented in March 2013; Laramie, WY; [cited 2019 Dec 1]. Available from: http://www.uwagec.org/rightrisk/presentations/2013_03_26_DGriffithMarketing/1_Introduction/1_FourTypesPriceVariation.pdf.
- Bodoh-Creed A, Boehnke J, Hickman B. Using machine learning to predict price dispersion. Scholars at Harvard; [cited 2020 Dec 1]. Available from: https://scholar.harvard.edu/files/boehnke/files/bcbh_machine_learning_price_dispersion.pdf.